Avison Young’s New Jersey office announced that Innocoll Biotherapeutics has signed a new long-term 10,000 s/f lease at 210 Carnegie Center to serve as the company’s new U.S. headquarters.
The new office space was unveiled yesterday afternoon at a ribbon cutting ceremony with West Windsor Mayor Hemant Marathe, Innocoll CEO Louis Pascarella and Drew Persson of Avison Young’s New Jersey office. Innocoll relocated its U.S. operations to New Jersey from its previous office space at 3803 West Chester Pike in Newton Square, PA.
Avison Young’s Drew Persson, a Principal based in the firm’s New Jersey office, represented Innocoll in the relocation and expansion. The sublandlord, Labcorp, was represented by CBRE in the negotiations and the landlord Boston Properties was represented in house.
“Innocoll’s relocation and expansion not only speaks to the company’s continued growth and the biopharmaceutical industry’s need for its revolutionary products, but to the value of New Jersey’s local talent pool to office occupiers,” said Persson.
Innocoll is a biotherapeutics pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet some of today’s most important healthcare challenges by utilizing its proprietary collagen-based technology platform to develop biodegradable and fully resorbable products. The company’s current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management in an effort to combat the opioid epidemic while simultaneously cutting down recovery time.
“Avison Young understood the type of property and location that would align with our expansion plans as we continue to grow and pursue new business opportunities. Relocating to Princeton provides us with access to a strong life sciences talent pool in an amenity-rich property,” said Louis Pascarella, CEO of Innocoll.
(Visited 1 times, 33 visits today)